Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(63%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
4
50%
Ph phase_1
1
13%
Ph phase_2
3
38%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(6)
Completed(2)

Detailed Status

Recruiting4
Completed2
Active, not recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 34 (50.0%)

Trials by Status

active_not_recruiting113%
enrolling_by_invitation113%
completed225%
recruiting450%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357
recruitingphase_3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800
completedphase_2

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970
enrolling_by_invitationphase_3

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT07444489
recruitingphase_2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

NCT07219043
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06935357Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Recruiting
NCT06962800Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Recruiting
NCT05065970Phase 2

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Completed
NCT07444489Phase 3

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Enrolling By Invitation
NCT07219043Phase 2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Recruiting
NCT06685757Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Recruiting
NCT06064929Phase 1

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

Active Not Recruiting
NCT05021484Phase 2

Felzartamab in Late Antibody-Mediated Rejection

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8